Figure 10.
An immune therapy by hsc70 fusion protein for established tumor. (a) On day 0, mice were challenged with a 1 × 106 E.G7 tumor. At day 6, 2 × 106 OTI CD8+T cells were injected via tail vein, and simultaneously, 10 µg hsc70‐OVA257‐264 or equal molar PA28α‐OVA257‐264 was once peritoneally injected. Tumor diameter was monitored every 2–3 days. (n = 4). (b) Carboxyfluorescein succinimidyl ester (CFSE)–labeled 2 × 106 OTI CD8+T cells were adoptively transferred into C57BL/6 mice and simultaneously vaccinated with 10 µg hsc70‐OVA257‐264 (panel 2) or equal molar PA28α‐OVA257‐264 (panel 3). Control mice were not injected with any proteins (column 1). Three days later, proliferating OTI CD8+ T cells in the spleen were investigated by carboxyfluorescein succinimidyl ester dilution (CFSE) and CD44.